CD4 and myeloid sarcoma: In TMEV- IDD mice, CB1R and CB2R agonists showed an enhanced clinical benefits through immunomodulatory and anti- inflammatory mechanisms such as activation of CD4+ T cells, increase in regulatory CD4+ T cells in the CNS along with alterations in the cytokine and chemokine milieu (189, 190), which is another evidence for the role of CB2Rs in MS.